Bristol-Myers Squibb Co (NYSE:BMY) – Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, according to Zacks Investment Research. Leerink Swann analyst S. Fernandez forecasts that the biopharmaceutical company will post earnings per share of $0.74 for the quarter. Leerink Swann has a “Positive” rating and a $76.00 price objective on the stock. Leerink Swann also issued estimates for Bristol-Myers Squibb’s Q2 2018 earnings at $0.76 EPS, Q3 2018 earnings at $0.77 EPS and Q4 2018 earnings at $0.84 EPS.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 EPS.
Several other analysts have also recently weighed in on the company. Zacks Investment Research cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price target for the company. in a research note on Thursday, December 28th. SunTrust Banks raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Thursday, October 26th. Finally, Citigroup set a $72.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Tuesday, December 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $65.58.
Shares of Bristol-Myers Squibb (BMY) opened at $63.87 on Wednesday. The firm has a market capitalization of $103,373.98, a PE ratio of 108.25, a price-to-earnings-growth ratio of 1.96 and a beta of 1.09. Bristol-Myers Squibb has a twelve month low of $51.56 and a twelve month high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.51%. The ex-dividend date of this dividend was Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.
In other news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MANA Advisors LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at $1,232,000. Nippon Life Global Investors Americas Inc. raised its stake in Bristol-Myers Squibb by 2.9% in the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 323,270 shares of the biopharmaceutical company’s stock valued at $19,809,000 after acquiring an additional 9,230 shares during the period. Renaissance Technologies LLC increased its position in Bristol-Myers Squibb by 31.9% during the 4th quarter. Renaissance Technologies LLC now owns 14,302,900 shares of the biopharmaceutical company’s stock worth $876,482,000 after buying an additional 3,456,300 shares during the period. Signaturefd LLC increased its position in Bristol-Myers Squibb by 22.0% during the 4th quarter. Signaturefd LLC now owns 18,229 shares of the biopharmaceutical company’s stock worth $1,117,000 after buying an additional 3,283 shares during the period. Finally, ETRADE Capital Management LLC increased its position in Bristol-Myers Squibb by 19.5% during the 4th quarter. ETRADE Capital Management LLC now owns 47,293 shares of the biopharmaceutical company’s stock worth $2,898,000 after buying an additional 7,712 shares during the period. Institutional investors and hedge funds own 69.56% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/14/leerink-swann-weighs-in-on-bristol-myers-squibb-cos-q1-2018-earnings-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.